PRE 14A

PRIMARY DOCUMENT

Company: NRX Pharmaceuticals, Inc.
Filed: April 26, 2019
Period of Report: April 26, 2019
Accession Number: 0001654954-19-004908

View Document ↗ View on SEC.gov ↗